SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study
- Written by PR Newswire
SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel
TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie, which has developed a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive...
